Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|12|4|649-652

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.12, Iss.4, 2014-07, pp. : 649-652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Target achievement with maximal statin‐based lipid‐lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis

By  

Clinical Cardiology, Vol. 40, Iss. 12, 2017-12 ,pp. : 1291-1296

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improving practice - Lipid disorders

By Morrell Jonathan  

Drugs In Context Primary Care Part A: Cardiovascular Medicine I, Vol. 1, Iss. 6, 2004-09 ,pp. : 233-238

CSF Medical Communications Ltd

Access to resources Recommend Favorite

Disease overview - Lipid disorders

By Clark Richard  

Drugs In Context Primary Care Part B: Cardiovascular Medicine II, Vol. 1, Iss. 7, 2004-09 ,pp. : 259-270

CSF Medical Communications Ltd

Access to resources Recommend Favorite

Disease overview - Lipid disorders

By Clark Richard  

Drugs In Context Primary Care Part B: Cardiovascular Medicine II, Vol. 1, Iss. 2, 2004-01 ,pp. : 43-54

CSF Medical Communications Ltd

Access to resources Recommend Favorite

Disease overview - Lipid disorders

By Clark Richard   Palmer Anna  

Drugs In Context Primary Care Part A: Cardiovascular Medicine I, Vol. 1, Iss. 9, 2004-12 ,pp. : 328-340

CSF Medical Communications Ltd

Access to resources Recommend Favorite